HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chromatin

The material of CHROMOSOMES. It is a complex of DNA; HISTONES; and nonhistone proteins (CHROMOSOMAL PROTEINS, NON-HISTONE) found within the nucleus of a cell.
Also Known As:
Chromatins
Networked: 13968 relevant articles (132 outcomes, 1047 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Li, Wei: 38 articles (01/2022 - 07/2005)
2. Akbarian, Schahram: 29 articles (08/2022 - 08/2005)
3. Garcia, Benjamin A: 26 articles (01/2022 - 12/2010)
4. Lupien, Mathieu: 26 articles (01/2022 - 01/2011)
5. Zhang, Wei: 25 articles (01/2022 - 07/2007)
6. Wang, Jing: 24 articles (06/2022 - 07/2004)
7. Armstrong, Scott A: 24 articles (01/2022 - 04/2010)
8. Chang, Howard Y: 24 articles (01/2021 - 06/2007)
9. Wang, Wei: 22 articles (06/2022 - 12/2009)
10. El-Osta, Assam: 22 articles (04/2022 - 11/2003)

Related Diseases

1. Neoplasms (Cancer)
11/01/2019 - "Furthermore, ecDNA is shown to have a significantly greater number of ultra-long-range interactions with active chromatin, which provides insight into how the structure of circular ecDNA affects oncogene function, and connects ecDNA biology with modern cancer genomics and epigenetics."
01/01/2017 - "In trying to resolve this contradiction, we show that during growth conditions, tumor progression is associated with global chromatin de-condensation that is beneficial for faster proliferation. "
06/28/2022 - "目的: 鼻咽癌(nasopharyngeal carcinoma,NPC)是一种高侵袭性的上皮源性恶性肿瘤,具有独特的地理和种族分布特征,多发于中国南方和东南亚地区,其治疗主要依靠放射治疗和化学治疗。但NPC通常发现于晚期,且常出现局部复发和远处转移,患者预后较差。受体酪氨酸激酶AXL在多种肿瘤中表达上调,参与肿瘤增殖、迁移、侵袭等过程,与肿瘤不良预后相关。本研究旨在检测AXL在NPC细胞系及组织中的表达,探讨AXL在NPC中的生物学功能及表达调控的分子机制。方法: 利用基因表达综合(Gene Expression Omnibus,GEO)数据库中的GSE68799、GSE12452、GSE53819三个数据集分析AXL在正常鼻咽上皮组织及NPC组织中的表达水平,利用癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库分析AXL与头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSC)患者预后的关系,包括总生存时间(overall survival,OS)、无病生存期(disease-free interval,DFI)、疾病特异性生存期(disease-specific survival,DSS)及无进展生存期(progression-free interval,PFI)4个预后指标;采用蛋白质印迹法检测AXL在正常鼻咽上皮细胞系及NPC细胞系中的蛋白质表达水平,免疫组织化学实验检测AXL在正常鼻咽上皮组织及NPC组织中的表达;利用慢病毒干扰载体包装病毒感染5-8F和Fadu细胞建立稳定敲低AXL的细胞系,利用慢病毒表达载体包装病毒感染C666-1和HK-1细胞建立稳定过表达AXL的细胞系,并通过real-time PCR及蛋白质印迹法检测稳转细胞系的干扰和过表达效率;利用CCK-8、平板克隆形成实验及Transwell实验检测敲低或过表达AXL对NPC细胞增殖、迁移及侵袭能力的影响,利用裸鼠皮下成瘤实验检测敲低AXL对裸鼠体内肿瘤生长的影响;利用UCSC在线数据库查询并获取AXL上游2.0 kb启动子区域的碱基序列,将序列输入PROMO在线数据库中以容错率0%为条件预测AXL的转录因子,并利用JASPAR在线数据库预测ETS1与AXL的结合位点;通过real-time PCR及蛋白质印迹法检测ETS1表达改变对AXL蛋白及mRNA表达水平的影响;将AXL上游2.0 kb启动子区域划分为8个片段,每个片段长度为250 bp,分别针对8个片段设计引物,利用染色质免疫沉淀(chromatin immuno-precipitation,ChIP)实验检测ETS1与AXL启动子区域的结合,明确ETS1对AXL的直接调控关系;利用功能回复实验检测ETS1是否通过AXL影响NPC细胞的增殖、迁移及侵袭能力。结果: 生物信息学分析发现AXL在NPC组织中高表达(P<0.05),且AXL高表达与HNSC患者更短的OS、DFI、DSS及PFI呈正相关。蛋白质印迹及免疫组织化学实验结果显示:相对于正常鼻咽上皮细胞系及组织,AXL在NPC细胞系及组织中高表达。Real-time PCR及蛋白质印迹实验结果显示:稳转细胞系的干扰及过表达效率满足后续实验要求。CCK-8、平板克隆形成实验、Transwell实验及裸鼠皮下成瘤实验结果表明:AXL表达下调显著抑制NPC细胞的增殖、迁移、侵袭及肿瘤生长(均P<0.05),AXL表达上调显著促进NPC细胞的增殖、迁移及侵袭(均P<0.05)。PROMO及JASPAR在线数据库预测结果显示:ETS1是AXL的转录因子,且与AXL启动子区域存在多个结合位点。Real-time PCR及蛋白质印迹法结果显示:敲低或过表达ETS1能够下调或上调AXL蛋白及mRNA的表达水平。ChIP实验结果显示:ETS1能与AXL的启动子区域结合,直接调控AXL的表达。功能回复实验结果显示:AXL能够回复ETS1对NPC细胞增殖、迁移及侵袭能力的影响(P<0.05)。结论: AXL在NPC细胞系及组织中高表达,能促进NPC的恶性进展,其表达受转录因子ETS1的调控。."
01/01/2022 - "Additionally, ZRT-2 showed better anti-cancer potential against A431 cells as seen by MTT assay, ROS generation and chromatin condensation analyses. "
05/28/2001 - "Understanding the molecular determinants of both normal and abnormal patterns of chromatin formation and DNA methylation thus holds great promise for our understanding of cancer and for means to better diagnose, prevent, and treat this disease."
2. Leukemia
3. Breast Neoplasms (Breast Cancer)
4. Aneuploidy (Aneuploid)
5. Infections

Related Drugs and Biologics

1. DNA (Deoxyribonucleic Acid)
2. Histones (Histone)
3. Histone Deacetylase Inhibitors
4. Proteins (Proteins, Gene)
5. Histone Deacetylases (Histone Deacetylase)
6. Biomarkers (Surrogate Marker)
7. RNA (Ribonucleic Acid)
8. Enzymes
9. Lysine (L-Lysine)
10. MicroRNAs (MicroRNA)

Related Therapies and Procedures

1. Therapeutics
2. Immunotherapy
3. Transplantation
4. Precision Medicine
5. Drug Therapy (Chemotherapy)